Stop Using ‘Natural’ Peptides to Treat Tendon Pain

If you spend any time in South African gym communities, CrossFit boxes, or trail-running WhatsApp groups, you’ve likely seen someone swear by BPC-157 — a peptide compound injected subcutaneously or taken orally, claimed to heal torn tendons and ligaments in weeks rather than months. The posts are convincing. The before-and-after timelines are dramatic. The science referenced sounds legitimate. Almost none of it applies to you.

Where the BPC-157 claim comes from

Body Protection Compound 157 is a synthetic peptide derived from a protein found in human gastric juice. Researchers began studying it in the 1990s, primarily in rodent models, and some of those studies did show accelerated tendon and ligament healing in rats and rabbits — faster collagen organisation, improved blood vessel formation, reduced inflammation markers.

That legitimate-sounding research is the foundation of the entire viral claim. Fitness influencers and peptide vendors cite phrases like “angiogenesis promotion” and “growth factor upregulation” — real biological mechanisms — without mentioning that every study producing those results was conducted on animals, mostly rats with surgically severed Achilles tendons.

The crucial point, which rarely makes the social media caption: a biological effect in a rat model tells you almost nothing reliable about what will happen in a human tendon. Rodent connective tissue heals differently, rodent studies cannot account for the complexity of chronic human tendinopathy, and the doses used in animal research do not translate cleanly to human physiology.

What the evidence actually says

No peer-reviewed, randomised controlled trial testing BPC-157 on human tendons or ligaments has been published. Not one. This is not a gap that the next study will quietly fill —it represents a complete absence of the clinical evidence required before a treatment can be recommended.

The South African Sports Medicine Association and sports physicians affiliated with the South African Medical Research Council’s non-communicable disease research units do not endorse BPC-157 for tendinopathy. No South African regulatory approval exists for its use in musculoskeletal injury. The South African Health Products Regulatory Authority has not registered BPC-157 as a medicine for any indication, which means locally sold products exist in a legal grey area with no quality-control guarantees.

To understand how significant this gap is: a 2023 systematic review in the British Journal of Sports Medicine found zero eligible human trials for BPC-157 across any musculoskeletal indication. When reviewers set a minimum bar of “published human data,” the compound had nothing to offer.

The nuance that’s being missed

It would be unfair to say BPC-157 is proven harmful. It is not. The more accurate statement is that it is unproven — in both directions. You do not know what you are injecting, at what dose, with what contaminants, or what it will do to your tendon tissue over five or ten years. People who report recovery after using it have almost always also been doing some form of rehabilitation exercise, rest, or load modification simultaneously. That makes it impossible to credit the peptide.

There is also a specific concern for South African users: individuals living with human immunodeficiency virus on antiretroviral therapy, or those managing type 2 diabetes — both highly prevalent in South Africa — face unknown drug interaction risks with unregulated injectables. No interaction data exists because no human trials exist.

What the evidence actually supports

Progressive tendon loading — a structured physiotherapy programme that gradually increases mechanical stress through the tendon — is the gold standard for tendinopathy, supported by multiple high-quality randomised controlled trials in humans.

The mechanism is direct and measurable: mechanical load stimulates tenocytes (tendon cells) to produce collagen, reorganise fibre alignment, and increase tendon stiffness. A 2015 landmark trial published in the Scandinavian Journal of Medicine and Science in Sports showed that heavy slow resistance training produced equivalent long-term outcomes to eccentric-only protocols for patellar and Achilles tendinopathy — both significantly better than passive treatment.

South African physiotherapists trained through the South African Society of Physiotherapy routinely use these protocols. A standard Achilles tendinopathy programme runs eight to 12 weeks, uses bodyweight or loaded calf raises progressed systematically, and costs between R400 and R800 per session in the private sector. Many medical aid plans cover physiotherapy under general benefits or as a prescribed minimum benefit where the tendinopathy is linked to a PMB condition.

Getting treatment in South Africa

Public sector: A community health centre or district hospital outpatient physiotherapy department is your first point of contact. Referral from a general practitioner at a public clinic is usually required. Waiting times vary by province, and load-shedding can affect appointment scheduling at facilities without backup generators — call ahead and confirm.

Private sector: A sports medicine physician consultation runs R900 to R1,800 for an initial appointment in major cities. Physiotherapy sessions range from R400 to R800 depending on the practice. A full 12-week rehabilitation programme may cost R6,000 to R12,000 privately. Medical aid members should check whether their plan covers physiotherapy sessions without a specialist referral — most open and comprehensive plans do, with an annual session limit.

Prescribed minimum benefit consideration: Tendinopathy alone is not a prescribed minimum benefit condition under current South African regulations. However, if your tendon injury is associated with a prescribed minimum benefit diagnosis — for example, diabetic neuropathy complications or a sports injury requiring hospitalisation — your medical aid cannot refuse to fund related rehabilitation.

Practical barrier: In rural provinces, accessing a physiotherapist at all may require travel to the nearest town. A general practitioner who can teach basic eccentric loading exercises is a reasonable first step while a referral is arranged.

When to see a doctor or physiotherapist

See a healthcare professional before starting any tendon rehabilitation programme if you experience sudden, sharp tendon pain (possible rupture), pain that wakes you at night, swelling with redness and warmth, or if you have not improved after six weeks of self-directed rest. If you are on antiretroviral therapy, chronic medication for diabetes, or blood thinners, speak to your doctor before using any injectable compound — regulated or not.

The bottom line

Reject the rat-study evidence: Every positive BPC-157 tendon study was conducted in rodents; zero human randomised controlled trials exist.
Choose progressive loading: A structured physiotherapy programme produces documented, measurable collagen remodelling — the same outcome BPC-157 claims to deliver, with actual human proof.

Check your source: BPC-157 is unregistered with the South African Health Products Regulatory Authority; you have no guarantee of what is in the vial.

Use the public pathway: Community health centre physiotherapy is free at point of access — ask your clinic for a referral rather than spending money on unproven compounds.
Name the real risk: if you are managing human immunodeficiency virus, diabetes, or tuberculosis, unregulated injectables carry unknown interaction risks that no study has yet assessed.